SNPMiner Trials (Home Page)
Report for Mutation Q192R
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 Paraoxonase and LDL Oxidation in Carotid Artery Disease
Atherosclerosis of the carotid arteries is a common cause of stroke. The prevalence and progression of carotid atherosclerosis are believed to be influenced by genetically inherited variations in lipoprotein metabolism. This study investigates the specific role of paraoxonase, an enzyme thought to detoxify atherogenic oxidized low-density lipoprotein. This study compares veterans who have significant carotid atherosclerosis on ultrasound examination with controls without carotid atherosclerosis. Both paraoxonase activity and genotype will be determined and compared between groups. The results may eventually make it possible to screen for a paraoxonase allele that confers high risk of atherosclerosis, and to diminish the risk by early treatment.
NCT00011258 Carotid Stenosis Drug: Paraoxonase MeSH:Carotid Stenosis Carotid Artery Diseases
HPO:Carotid artery stenosis
Two paraoxonase (PON1) polymorphisms, PON1-Q192R and PON1-L55M have been inconsistently associated with vascular disease. --- Q192R ---
2 Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
NCT02707445 Myocardial Ischemia CLOPIDOGREL, POOR METABOLISM of (Disorder) Drug: Clopidogrel MeSH:Myocardial Ischemia Ischemia
HPO:Myocardial infarction
Genes which are known to be related with clopidogrel resistance were evaluated; (1-3) CYP 2C19 *2, *3, *17, (4) PON1 Q192R, (5) ABCB1 3435C->T, (6) P2Y12, (7) CYP 2C9 *3. --- Q192R ---
Primary Outcomes
Measure: Myocardial infarction and Death Time: 1 year after index procedureSecondary Outcomes
Measure: Any death Time: 1 year after index procedureMeasure: Cardiac death Time: 1 year after index procedure
Measure: Myocardial infarction Time: 1 year after index procedure
Measure: Stent thrombosis (acute, late, very late) Time: 1 year after index procedure
Description: Revascularization of in-stent restenosis which developed in previously implanted stent on index procedure
Measure: Target lesion revascularization Time: 1 year after index procedureDescription: Ischemic or hemorrhagic cerebral infarction diagnosed by brain MRI which developed within 1 year after index procedure
Measure: Stroke Time: 1 year after index procedureMeasure: Bleeding complication Time: During index procedure
Description: Value which is measured with VerifyNow that can monitor platelet inhibition of clopidogrel
Measure: PRU Time: Within index procedureDescription: Value which is measured with VerifyNow that can monitor platelet inhibition of aspirin
Measure: ARU Time: Within index procedure